AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Prothena Corporation plc (NASDAQ:PRTA)
5.15 USD
-0.260 4.806%Sponsored Reports
Loading...
| Previous Close (in USD) | 5.41 |
|---|---|
| Change | -0.260 4.806% |
| 52 W H/L (in USD) | 77.130/19.650 |
| EBITDA (in USD) | -215.297M |
| PE Ratio | -- |
| Volume | 1775275 |
| Diluted Eps TTM | -3.21 |
| Total Assets (in USD) | 696.382M |
|---|---|
| Total Liabilities (in USD) | 135.017M |
| Revenue TTM (in USD) | 89.251M |
| Cash (in USD) | 620.182M |
| Market Cap (in USD) | 1,072.748 M |
| Revenue Per Share TTM | 1.668 |
| Gross Profit TTM (in USD) | -81.657M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.
Employees: 173
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Gene G. Kinney Ph.D. | Pres, CEO & Director | 1969 |
| 2. | Mr. Tran B. Nguyen M.B.A. | CFO & Chief Strategy Officer | 1974 |
| 3. | Mr. Brandon S. Smith | Chief Operating Officer | 1975 |
| 4. | Ms. Carol D. Karp | Chief Regulatory Officer | 1953 |
| 5. | Dr. Hideki Garren M.D., Ph.D. | Chief Medical Officer | 1965 |
| 6. | Ms. Karin L. Walker CPA, CPA | Chief Accounting Officer & Controller | 1963 |
| 7. | Dr. Wagner M. Zago | Chief Scientific Officer | 1973 |
| 8. | Ms. Jennifer Zibuda | Director of Investor Relations & Communication | NA |
| 9. | Mr. Michael J. Malecek | Chief Legal Officer | 1966 |
| 10. | Ms. Yvonne M. Tchrakian | Company Sec. | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
+0.820 1.099% | 75.01 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
+1.680 2.288% | 74.6 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-2.960 0.657% | 450.78 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+20.100 4.075% | 498 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Income Before Tax | -160.48M | -125.605M | 71.921M | -111.427M | -77.298M |
| Minority Interest | - | - | - | - | - |
| Net Income | -147.028M | -116.949M | 66.975M | -111.144M | -77.677M |
| Selling General Administrative | 61.835M | 49.9M | 46.318M | 38.703M | 35.736M |
| Gross Profit | 82.958M | 53.905M | 200.577M | 0.853M | -50.022M |
| Reconciled Depreciation | 0.928M | 0.744M | 6.803M | 6.977M | 6.82M |
| Ebit | -191.036M | -131.557M | 71.975M | -112.734M | -85.697M |
| Ebitda | -190.108M | -130.813M | 78.778M | -105.757M | -85.819M |
| Depreciation And Amortization | 0.928M | 0.744M | 6.803M | 6.977M | -0.122M |
| Operating Income | -191.036M | -131.557M | 71.975M | -112.734M | -85.697M |
| Other Operating Expenses | 282.406M | 185.462M | 128.602M | 113.587M | 86.572M |
| Interest Expense | - | 6.696M | 6.749M | 8.284M | 8.203M |
| Tax Provision | -13.452M | -8.656M | 4.946M | -0.283M | 0.379M |
| Interest Income | 31.014M | 6.349M | 0.042M | 1.369M | 8.203M |
| Net Interest Income | 31.014M | 6.349M | 0.042M | 1.369M | 8.203M |
| Income Tax Expense | -13.452M | -8.656M | 4.946M | -0.283M | 0.379M |
| Total Revenue | 91.37M | 53.905M | 200.577M | 0.853M | 0.814M |
| Total Operating Expenses | 282.406M | 185.462M | 128.602M | 113.587M | 86.572M |
| Cost Of Revenue | 8.412M | 6.741M | 82.284M | 74.884M | 50.836M |
| Total Other Income Expense Net | 30.556M | 5.952M | -0.054M | 1.307M | 8.399M |
| Net Income From Continuing Ops | -147.028M | -116.949M | 66.975M | -111.144M | -77.677M |
| Net Income Applicable To Common Shares | - | -116.949M | 66.975M | -111.144M | -77.677M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 696.382M | 758.035M | 609.366M | 332.975M | 419.268M |
| Intangible Assets | - | - | - | - | - |
| Other Current Assets | 19.1M | 8.692M | 5.715M | 2.537M | 2.652M |
| Total Liab | 135.017M | 135.993M | 143.324M | 148.969M | 146.347M |
| Total Stockholder Equity | 561.365M | 622.042M | 466.042M | 184.006M | 272.921M |
| Other Current Liab | -37.019M | 22.962M | 16.164M | 11.292M | 6.787M |
| Common Stock | 0.537M | 0.521M | 0.466M | 0.399M | 0.399M |
| Capital Stock | 0.537M | 0.521M | 0.466M | 0.399M | 0.399M |
| Retained Earnings | -980.031M | -833.003M | -716.054M | -783.029M | -671.885M |
| Good Will | - | - | - | - | - |
| Other Assets | - | 30.929M | 10.422M | 31.14M | 13.745M |
| Cash | 620.182M | 710.406M | 579.094M | 295.38M | 375.723M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 56.891M | 50.147M | 33.452M | 25.848M | 17.714M |
| Current Deferred Revenue | 67.405M | 11.442M | 7.657M | 4.927M | 4.584M |
| Net Debt | -608.347M | -703.933M | -566.768M | -277.542M | -352.784M |
| Short Term Debt | 1.114M | 6.473M | 5.94M | 5.512M | 5.101M |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | 11.835M | 6.473M | 12.326M | 17.838M | 22.939M |
| Other Stockholder Equity | 1540.859M | 1454.524M | 1181.63M | 966.636M | 944.407M |
| Property Plant Equipment | - | 8.008M | 2.012M | 2.551M | 3.874M |
| Total Current Assets | 639.282M | 719.098M | 584.809M | 299.284M | 378.375M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | 5.159M | 0.062M | 0.013M | 0.015M | 0.068M |
| Long Term Debt | - | - | - | - | - |
| Inventory | -5.159M | -0.062M | - | 1.352M | -0.068M |
| Accounts Payable | 25.391M | 9.27M | 3.691M | 4.117M | 1.242M |
| Accumulated Other Comprehensive Income | - | - | - | - | -8.007M |
| Non Currrent Assets Other | 40.242M | 12.725M | 3.351M | 1.685M | 3.789M |
| Non Current Assets Total | 57.1M | 38.937M | 24.557M | 33.691M | 40.893M |
| Capital Lease Obligations | 11.835M | 6.473M | 12.326M | 17.838M | 22.939M |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Investments | -1.412M | -0.464M | -0.575M | -0.196M | -0.547M |
| Total Cashflows From Investing Activities | - | -0.464M | -0.575M | -0.196M | -0.547M |
| Total Cash From Financing Activities | 45.103M | 241.457M | 190.332M | 0.215M | 0.228M |
| Net Income | -147.028M | -116.949M | 66.975M | -111.144M | -77.677M |
| Change In Cash | -90.224M | 132.172M | 282.362M | -80.343M | -53.288M |
| Begin Period Cash Flow | 710.406M | 580.446M | 298.084M | 378.427M | 431.715M |
| End Period Cash Flow | 620.182M | 712.618M | 580.446M | 298.084M | 378.427M |
| Total Cash From Operating Activities | -133.906M | -108.821M | 92.605M | -80.362M | -52.969M |
| Depreciation | 0.928M | 0.744M | 6.803M | 6.977M | 6.82M |
| Other Cashflows From Investing Activities | - | - | - | - | 0.008M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -8.896M | - | -10.275M | - | - |
| Sale Purchase Of Stock | - | - | 93.593M | 0.215M | 0.228M |
| Other Cashflows From Financing Activities | 45.103M | 17.841M | 190.332M | 0.215M | 0.228M |
| Capital Expenditures | 2.81M | 0.464M | 0.575M | 0.196M | 0.555M |
| Change In Working Capital | -20.53M | -18.803M | -10.404M | 3.479M | -4.449M |
| Other Non Cash Items | 7.499M | 5.998M | 38.741M | 28.187M | 51.354M |
| Free Cash Flow | -136.716M | -109.285M | 92.03M | -80.558M | -53.524M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Growth Compy Commingled Pl O | 1 year ago | 3195759 |
| 2. | Vanguard Health Care Inv | 1 year ago | 2394263 |
| 3. | SPDR® S&P Biotech ETF | 1 year ago | 2356051 |
| 4. | Fidelity Growth Company Fund | 1 year ago | 2345924 |
| 5. | T. Rowe Price New Horizons | 1 year ago | 1903007 |
| 6. | US Small-Cap Growth II Equity Comp | 1 year ago | 1903007 |
| 7. | iShares Russell 2000 ETF | 1 year ago | 977664 |
| 8. | Fidelity Growth Company K6 | 1 year ago | 835101 |
| 9. | Fidelity Select Biotechnology | 1 year ago | 801417 |
| 10. | Fidelity Series Growth Company | 1 year ago | 749705 |
| 11. | T. Rowe Price Health Sciences | 1 year ago | 622907 |
| 12. | Vanguard Institutional Extnd Mkt Idx Tr | 1 year ago | 581839 |
| 13. | Janus Henderson Global Life Sciences D | 1 year ago | 563168 |
| 14. | Janus Henderson Global Life Sciences | 1 year ago | 563168 |
| 15. | Eventide Healthcare & Life Sciences I | 1 year ago | 445155 |
| 16. | Janus Selection Global Life Science AUSD | 1 year ago | 432056 |
| 17. | Janus Henderson Glb Life Scn I2 USD | 1 year ago | 432056 |
| 18. | Fidelity Small Cap Index | 1 year ago | 430913 |
| 19. | T. Rowe Price Integrated US Sm Gr Eq | 1 year ago | 418230 |
| 20. | T. Rowe Price New Horizons Tr-Z | 1 year ago | 369045 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | EcoR1 Capital, LLC | 1 year ago | 11584280 |
| 2. | FMR Inc | 1 year ago | 8049796 |
| 3. | T. Rowe Price Associates, Inc. | 1 year ago | 4201771 |
| 4. | BlackRock Inc | 1 year ago | 3770650 |
| 5. | State Street Corporation | 1 year ago | 2758564 |
| 6. | Wellington Management Company LLP | 1 year ago | 2594102 |
| 7. | Palo Alto Investors, LLC | 1 year ago | 1663448 |
| 8. | HHG PLC | 1 year ago | 1309590 |
| 9. | Vanguard Group Inc | 1 year ago | 1125283 |
| 10. | Armistice Capital, LLC | 1 year ago | 1096000 |
| 11. | Geode Capital Management, LLC | 1 year ago | 905125 |
| 12. | Dimensional Fund Advisors, Inc. | 1 year ago | 862832 |
| 13. | Boxer Capital LLC | 1 year ago | 690000 |
| 14. | Goldman Sachs Group Inc | 1 year ago | 667572 |
| 15. | Rock Springs Capital Management LP | 1 year ago | 625048 |
| 16. | Artal Group S A | 1 year ago | 501360 |
| 17. | Morgan Stanley - Brokerage Accounts | 1 year ago | 482260 |
| 18. | First Light Asset Management, LLC | 1 year ago | 444953 |
| 19. | Bank of New York Mellon Corp | 1 year ago | 442309 |
| 20. | Northern Trust Corp | 1 year ago | 404110 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...